ID

36650

Description

A Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least Two Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT02409368

Lien

https://clinicaltrials.gov/show/NCT02409368

Mots-clés

Versions (2)
  1. 28/05/2019 28/05/2019 -
  2. 28/05/2019 28/05/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

28 mai 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Non-Small Cell Lung Cancer NCT02409368

Anglais

Eligibility Non-Small Cell Lung Cancer NCT02409368

1 Formulaires  
Criteria
Description

Criteria

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
easter cooperative oncology group (ecog) status: performance status (ps) 0-1 & ps 2
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
subjects with histologically or cytologically-documented sqnsclc
Description

Squamous non-small cell lung cancer

Type de données

boolean

Alias
UMLS CUI [1]
C4509816
subjects must have experienced disease progression or recurrence during or after both a platinum doublet-based chemotherapy regimen and at least 1 additional systemic therapy
Description

Disease Progression | Recurrence | Status post Chemotherapy Platinum-Based Double | Status post Systemic therapy Quantity

Type de données

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2]
C0034897
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C0392920
UMLS CUI [3,3]
C1514162
UMLS CUI [3,4]
C0205173
UMLS CUI [4,1]
C0231290
UMLS CUI [4,2]
C1515119
UMLS CUI [4,3]
C1265611
subjects must have evaluable disease by ct or mri per response evaluation criteria in solid tumors (recist 1.1) criteria
Description

Evaluable Disease CT | Evaluable Disease MRI

Type de données

boolean

Alias
UMLS CUI [1,1]
C1516986
UMLS CUI [1,2]
C0040405
UMLS CUI [2,1]
C1516986
UMLS CUI [2,2]
C0024485
subjects with treated or asymptomatic cns metastases
Description

CNS metastases Treated | CNS metastases Asymptomatic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C1522326
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231221
prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
Description

Palliative course of radiotherapy Completed

Type de données

boolean

Alias
UMLS CUI [1,1]
C0475092
UMLS CUI [1,2]
C0205197
males and females, ages 18 or older
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with untreated, symptomatic cns metastases
Description

CNS metastases Untreated | CNS metastases Symptomatic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231220
subjects with carcinomatous meningitis
Description

Meningeal Carcinomatosis

Type de données

boolean

Alias
UMLS CUI [1]
C0220654
subjects with active, known or suspected autoimmune disease
Description

Autoimmune Disease | Autoimmune Disease Suspected

Type de données

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2,1]
C0004364
UMLS CUI [2,2]
C0750491
subjects who received prior therapy with anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody (including ipilimumab or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized bms clinical trial for nivolumab or ipilimumab
Description

Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody | ipilimumab | Monoclonal Antibodies | Targeted Therapy T cell costimulation | Study Subject Participation Status | nivolumab

Type de données

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C4289970
UMLS CUI [3]
C4289971
UMLS CUI [4,1]
C1705357
UMLS CUI [4,2]
C0003250
UMLS CUI [5,1]
C0214721
UMLS CUI [5,2]
C0003250
UMLS CUI [6]
C4289973
UMLS CUI [7]
C1367202
UMLS CUI [8]
C0003250
UMLS CUI [9,1]
C2985566
UMLS CUI [9,2]
C1622572
UMLS CUI [10]
C2348568
UMLS CUI [11]
C3657270
Retour au début de la page

Similar models

Eligibility Non-Small Cell Lung Cancer NCT02409368

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Item Group
C1512693 (UMLS CUI)
ECOG performance status
Item
easter cooperative oncology group (ecog) status: performance status (ps) 0-1 & ps 2
boolean
C1520224 (UMLS CUI [1])
Squamous non-small cell lung cancer
Item
subjects with histologically or cytologically-documented sqnsclc
boolean
C4509816 (UMLS CUI [1])
Disease Progression | Recurrence | Status post Chemotherapy Platinum-Based Double | Status post Systemic therapy Quantity
Item
subjects must have experienced disease progression or recurrence during or after both a platinum doublet-based chemotherapy regimen and at least 1 additional systemic therapy
boolean
C0242656 (UMLS CUI [1])
C0034897 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C1514162 (UMLS CUI [3,3])
C0205173 (UMLS CUI [3,4])
C0231290 (UMLS CUI [4,1])
C1515119 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
Evaluable Disease CT | Evaluable Disease MRI
Item
subjects must have evaluable disease by ct or mri per response evaluation criteria in solid tumors (recist 1.1) criteria
boolean
C1516986 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
C1516986 (UMLS CUI [2,1])
C0024485 (UMLS CUI [2,2])
CNS metastases Treated | CNS metastases Asymptomatic
Item
subjects with treated or asymptomatic cns metastases
boolean
C0686377 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231221 (UMLS CUI [2,2])
Palliative course of radiotherapy Completed
Item
prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
boolean
C0475092 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
Age
Item
males and females, ages 18 or older
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
CNS metastases Untreated | CNS metastases Symptomatic
Item
subjects with untreated, symptomatic cns metastases
boolean
C0686377 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Meningeal Carcinomatosis
Item
subjects with carcinomatous meningitis
boolean
C0220654 (UMLS CUI [1])
Autoimmune Disease | Autoimmune Disease Suspected
Item
subjects with active, known or suspected autoimmune disease
boolean
C0004364 (UMLS CUI [1])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody | ipilimumab | Monoclonal Antibodies | Targeted Therapy T cell costimulation | Study Subject Participation Status | nivolumab
Item
subjects who received prior therapy with anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody (including ipilimumab or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized bms clinical trial for nivolumab or ipilimumab
boolean
C1514463 (UMLS CUI [1])
C4289970 (UMLS CUI [2])
C4289971 (UMLS CUI [3])
C1705357 (UMLS CUI [4,1])
C0003250 (UMLS CUI [4,2])
C0214721 (UMLS CUI [5,1])
C0003250 (UMLS CUI [5,2])
C4289973 (UMLS CUI [6])
C1367202 (UMLS CUI [7])
C0003250 (UMLS CUI [8])
C2985566 (UMLS CUI [9,1])
C1622572 (UMLS CUI [9,2])
C2348568 (UMLS CUI [10])
C3657270 (UMLS CUI [11])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial